In the phase III clinical trial for use in breast cancer, a combination of docetaxel, epirubicin, and recombinant endostatin (n = 401) compared to docetaxel and epirubicin alone (n = 402) was found to achieve more complete, partial, and overall responses [158]. Here, COL18A1 is linked to breast cancer.